Received Jun 29, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| RAB | RABIES (RABAVERT) | NOVARTIS VACCINES AND DIAGNOSTICS | 1 | Unknown | SC |
Patient received Rabavert subcutaneously; Case reference number US-BN-2025-000994 is a spontaneous case initially received from a pharmacist via agency (reference number: USBAV25-1246) on 28-May-2025 and concerns a 74-year-old female patient. The patient's medical history was not provided. The patient's concomitant medication details included levothyroxine and lisinopril. The patient's current condition included hypertension, hypothyroidism and obstructive sleep apnea. On an unspecified date, the patient had been exposure to the rabies virus. On 25-May-2025, reported as on day zero, the patient received the first dose of Rabavert along with its constituent parts prefilled syringe, needle for injection and needle for reconstitution (batch number: unknown), at unknown dose, subcutaneously at unknown site of administration for indication post exposure prophylaxis (explicitly coded as 'inappropriate route of vaccination'). At the time of the initial report, it was unknown if the patient experienced any adverse events due to Rabavert, as reported there was no documentation of reactionary effects of that administration. No further information was provided.; Reporter's Comments: A 74-year-old female patient received the first dose of Rabavert subcutaneously, for indication post exposure prophylaxis, which is considered as inappropriate route of vaccination. It was unknown if the patient experienced any adverse events due to Rabavert. Incorrect route of product administration is considered as listed per company convention. The patient's medical history was not provided, concomitant medication details included levothyroxine and lisinopril, and current condition included hypertension, hypothyroidism and obstructive sleep apnea. Incorrect route of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.; Sender's Comments: A 74-year-old female patient received the first dose of Rabavert subcutaneously, for indication post exposure prophylaxis, which is considered as inappropriate route of vaccination. It was unknown if the patient experienced any adverse events due to Rabavert. Incorrect route of product administration is considered as listed per company convention. The patient's medical history was not provided, concomitant medication details included levothyroxine and lisinopril, and current condition included hypertension, hypothyroidism and obstructive sleep apnea. Incorrect route of product administration is not related to the suspect vaccine, but to a human factor. This case is considered as non-serious.
Medical History/Concurrent Conditions: Hypertension; Hypothyroidism; Obstructive sleep apnea
LEVOTHYROXINE; LISINOPRIL